TWINSTRAND BIOSCIENCES INC
- SEATTLE, WA 98121-1095
- twinstrandbio.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $50K
- Awards on record
- 1
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
TWINSTRAND BIOSCIENCES INC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About TWINSTRAND BIOSCIENCES INC
- Headquarters
- SEATTLE, WA 98121-1095
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIHPY9BJWV8X31
- CAGE7R5X5
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $50K
- Awards on record
- 1
- Top funding agencies
- Food and Drug Administration
Awards
75F40124P00263
Completed: Period of performance ended Sep 25, 2024TWINSTRAND DUPLEX SEQUENCING MUTAGENESIS KIT
Department of Health and Human Services · Food and Drug Administration
- Obligated
- $50K
- Period of performance
- Jun 27, 2024 – Sep 25, 2024
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
75F40124P00263 TWINSTRAND DUPLEX SEQUENCING MUTAGENESIS KIT | Department of Health and Human Services · Food and Drug Administration | 541714 · 6640LABORATORY EQUIPMENT AND SUPPLIES | $50K | Jun 27, 2024 – Sep 25, 2024 | Completed: Period of performance ended Sep 25, 2024 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 7 awards
- Total awarded
- $9,679,058
- By phase
- SBIR Phase II: 4
- SBIR Phase I: 3
- By agency
- Department of Health and Human Services: 7
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 1 project
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2023: 1
- 2020: 1
- 2019: 2
- 2018: 2
- 2017: 1
Awards (most recent first)
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $3,124,934
Aug 15, 2023 – Jan 31, 2027
- Active
- Ends Jan 2027
Solicitation CA22-025 (2022) · Topic NCI
Development of a Genotoxicity Assay using Duplex Sequencing
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $1,494,048
Aug 20, 2020 – Jul 31, 2022
Solicitation PA18-574 (2018) · Topic R
Development of a Genotoxicity Assay using Duplex Sequencing
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $224,797
Jul 15, 2019 – Jan 31, 2020
Solicitation PA18-574 (2018) · Topic NIEHS
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,240,080
Jan 1, 2019 – Dec 31, 2021
Solicitation PA17-302 (2017) · Topic 102
Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $2,000,000
Sep 14, 2018 – Feb 28, 2021
Solicitation PA16-302 (2016) · Topic 102
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $299,790
Jul 16, 2018 – Jun 30, 2019
Solicitation PA17-302 (2017) · Topic 102
Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $295,409
Sep 1, 2017 – Feb 28, 2018
Solicitation PA16-302 (2016) · Topic 102
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Primary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with TWINSTRAND BIOSCIENCES INC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.